<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>2019 AACR | K药在广泛期SCLC患者中显示出令人鼓舞的抗肿瘤活性和持久反应 | 极客快訊</title><meta property="og:title" content="2019 AACR | K药在广泛期SCLC患者中显示出令人鼓舞的抗肿瘤活性和持久反应 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/RMO1D3wIM6bQ5S"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><meta property="article:published_time" content="2020-11-14T21:02:05+08:00"><meta property="article:modified_time" content="2020-11-14T21:02:05+08:00"><meta name=Keywords content><meta name=description content="2019 AACR | K药在广泛期SCLC患者中显示出令人鼓舞的抗肿瘤活性和持久反应"><meta name=author content="极客快訊"><meta property="og:url" content="/cn/%E7%A7%91%E6%8A%80/8cb2a5eb.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快讯 Geek Bank</a></h1><p class=description>为你带来最全的科技知识 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>2019 AACR | K药在广泛期SCLC患者中显示出令人鼓舞的抗肿瘤活性和持久反应</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E6%8A%80.html>科技</a></span></div><div class=post-content><img alt="2019 AACR | K药在广泛期SCLC患者中显示出令人鼓舞的抗肿瘤活性和持久反应" onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/RMO1D3wIM6bQ5S><p>2019年美国癌症研究协会(AACR)年会于2019年3月29日—4月3日在美国亚特兰大举行。AACR年会是世界上规模最大的癌症研究会议之一，今年AACR大会主题为“综合性癌症科学•全球影响•个性化患者护理”。免疫疗法依旧是今年AACR的一个重要主题。</p><p>3月28日，帕博利珠单抗（K药）一线治疗转移性非鳞状非小细胞肺癌（NSCLC）的适应证正式获批。这一重磅消息的余热还未散去，帕博利珠单抗的又一利好消息在2019年的AACR年会上被公布。</p><p>美国当地时间4月1日午间，韩国延世大学医学院延世癌症中心Hyun Cheol Chung教授公布了KEYNOTE-028和KEYNOTE-158试验的汇总分析，分析结果显示，帕博利珠单抗在预处理的晚期小细胞肺癌（SCLC）患者中表现出令人鼓舞的抗肿瘤活性和持久反应。</p><p><strong>研究方法</strong></p><p>该汇总分析仅关注KEYNOTE-028试验中的Ib期和KEYNOTE-158中的II期试验的SCLC队列，并对符合纳入分析要求的患者进行了组织学或细胞学证实，保证其满足无法治愈的晚期SCLC，标准治疗进展或失败，且未接受免疫治疗的条件。</p><p>两项试验共纳入131例SCLC患者，包括来自KEYNOTE-028的24名患者和来自KEYNOTE-158的107名患者。其中，83名接受过≥2次治疗的患者被确定有资格进行疗效分析。虽然参加KEYNOTE-028试验的患者需要患有PD-L1阳性肿瘤（综合阳性评分≥1），但这不是登记KEYNOTE-158所必需的。</p><p>在KEYNOTE-028中每8周进行一次放射成像，KEYNOTE-158中则每9周进行一次；KEYNOTE-028中6个月后每12周进行一次，KEYNOTE-158中则在进行1年后再改为每12周一次。试剂的剂量在两项试验中也存在差别。在KEYNOTE-028中每2周给予帕博利珠单抗 10mg / kg，而在KEYNOTE-158中则是每3周给予200mg剂量。给药剂持续2年或直至疾病进展或毒性不能耐受则终止。</p><p>两项研究的主要终点是相同的：总缓解率（ORR），根据RECIST 1.1标准评估。缓解持续时间（DOR），无进展生存期（PFS）和总生存期（OS）均作为次要终点，并且使用Kaplan-Meier方法进行估计。</p><p><strong>研究结果</strong></p><p>来自KEYNOTE-028的数据显示ORR为33.3%（95%CI，15.6%-55.3%）和DOR为19.4个月（3.6 +至20.0+）。就生存获益而言，使用帕博利珠单抗治疗后，患者的中位PFS为1.9个月（95%CI，1.7-5.9），中位OS为9.7个月（95%CI，4.1-未达到）。相比之下，在II期KEYNOTE-158试验中用PD-1抑制剂观察到的ORR为18.7%（95%CI，11.8%-27.4%），而DOR尚未达到（2.1+至18.7+）。该试验的中位PFS和OS分别为2.0个月（95%CI，1.9-2.1）和8.7个月（95%CI，5.6-12.0）。</p><p>汇总分析结果显示，ORR为19.3%（16例患者；95%CI，11.4%-29.4%），其中2例患者（2%）达到完全缓解，14例患者（17%）部分缓解，15例患者病情稳定（18%）。9名受访者（61%）的DOR≥18个月。</p><p>中位随访时间为7.7个月（0.5-48.7），研究者观察到中位PFS为2个月（95%CI，1.9-3.4），中位OS为7.7个月（95%CI，5.2-10.1）。在12个月的随访中，PFS率为17%，而OS率为34%；在24个月时，PFS和OS率分别为13%和21%。</p><p>值得注意的是，16名缓解者中有14名PD-L1阳性。由于两项试验有不同的评估PD-L1的方法，参与汇总分析的研究者并不打算评估PD-L1阳性在患者选择中的作用。</p><p>在分析中观察到不良事件（AE）与先前关于抗PD-1单克隆抗体的安全性特征的报道一致。在KEYNOTE-028和KEYNOTE-158两项试验的所有SCLC患者（N = 131）中，不考虑先前的治疗，8%出现3级治疗相关的AE（没有4级治疗相关的AE），3名患者出现5级治疗相关的AE（肠缺血、肺炎、脑病）。21%的患者经历过免疫介导的AE或输注反应。</p><p><strong>结论</strong></p><p>帕博利珠单抗在接受过两次或更多次治疗的广泛期SCLC患者中显示出令人鼓舞的抗肿瘤活性，且反应持久，大多数患者的缓解持续时间至少为18个月，并没有观察到帕博利珠单抗预期以外的毒性。</p><p><strong>英文摘要</strong></p><p><strong>Background: </strong>The antitumor activity of the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced SCLC has been evaluated in the Phase Ib basket study KEYNOTE-028 (KN028; NCT02054806) and in the Phase II basket study KEYNOTE-158 (KN158; NCT02628067). We present outcomes for patients enrolled in KN028 and KN158 who were receiving pembrolizumab after ≥2 lines of prior therapy.</p><p><strong>Methods:</strong>Eligible patients had histologically/cytologically confirmed incurable advanced SCLC, measurable disease per RECIST 1.1, ECOG PS of 0/1, had experienced progression/failure on standard therapy, and were immunotherapy-naive; patients included in this analysis had received ≥2 lines of systemic therapy. Patients in KN028 were required to have PD-L1-positive tumors (membranous PD-L1 expression in ≥1% of tumor and associated inflammatory cells or positive staining in stroma); tumor PD-L1 expression was not required in KN158. Radiographic imaging was performed Q8W for 6 mo (KN028) or Q9W for 1 y (KN158), and Q12W thereafter. Pembrolizumab (10 mg/kg Q2W [KN028] or 200 mg Q3W [KN158]) was administered for 2 y or until disease progression or intolerable toxicity. The primary endpoint in both studies was objective response rate (ORR) assessed per RECIST 1.1. Duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were secondary endpoints and estimated using the Kaplan-Meier method. For this analysis, assessment of response was by independent central review.</p><p><strong>Results:</strong>Of 131 SCLC pts included in both trials, 83 were eligible for efficacy analyses (KN158, n=64; KN028, n=19). Median age was 62 (range, 24‒84) y, 64% were men, and 36% had received ≥3 lines of systemic therapy. As of the data cutoff date, median follow-up was 7.7 (range, 0.5‒48.7) mo. The ORR was 19.3% (95% CI, 11.4-29.4). Two patients had a complete response and 14 had a partial response per independent central review; 14 of 16 responders were PD-L1-positive. Median DOR was not reached (range, 4.1-35.8 [ongoing] mo). 9 of 16 responders (61% per Kaplan-Meier estimate) had response lasting ≥18 mo. Median PFS was 2.0 (95% CI, 1.9-3.4) mo and median OS was 7.7 (95% CI, 5.2-10.1) mo. 12- and 24-month rates were 16.9% and 13.1% for PFS, and 34% and 21% for OS. Among all SCLC patients in KN028 and KN158 irrespective of prior therapies (N=131), 8% had a grade 3 treatment-related AE (no grade 4 treatment-related AEs). 3 patients had grade 5 treatment-related AEs (intestinal ischemia, pneumonia, encephalopathy). 21% experienced an immune-mediated AE or infusion reaction.</p><p><strong>Conclusions: </strong>Pembrolizumab demonstrated promising antitumor activity in patients with advanced SCLC who had received ≥2 lines of prior therapy. Responses were durable, with the majority of patients estimated to have a response duration of at least 18 mo. No unexpected toxicities from pembrolizumab were observed.</p><p>参考来源：</p><p>[1] Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies. Abstract CT073</p><p>[2] Pembrolizumab Shows Promising Antitumor Activity in Pretreated Patients with SCLC. Onclive/Conference-coverage/AACR-2019.Tuesday, Apr 02, 2019</p><p>2019 AACR 专题</p><p>长按识别二维码查看</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'2019','AACR','药在'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>